• Publications
  • Influence
Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis.
It is considered that certain dihydropyridine type calcium channel blockers would cause turbid peritoneal dialysate being similar to that observed in patients developing infective peritonitis. Expand
Protein binding of disopyramide in liver cirrhosis and in nephrotic syndrome
The results suggest that the D therapeutic range measured as the total plasma concentration in cirrhosis, but not in nephrosis, should be approximately 50% lower than previously believed. Expand
Hemofiltrability of H2‐Receptor Antagonist, Famotidine, in Renal Failure Patients
It is recommended that no supplemental doses of famotidine be required for patients with renal failure during or after the intermittent or continuous arteriovenous hemofiltration, as these clearance values are found to correspond to only 10 to 25% of the mean total body clearance reported from anuric patients. Expand
Hemofiltrability of Histamine H2‐Receptor Antagonist, Nizatidine, and its Metabolites in Patients with Renal Failure
It is recommended that no supplemental doses of nizatidine be required for patients with renal failure during or after such an intermittent hemofiltration as performed in the current study, and the respective Sc values for the compounds observed in theCurrent study could be extrapolated into a 24‐hour continuous arteriovenous hem ofiltration performed at a commonly used filtration rate. Expand
Altered Protein Binding of Disopyramide in Plasma from Patients with Cancer and with Inflammatory Disease
A therapeutic range of D measured as total drug concentration in patients with cancer and with inflammatory diseases would be greater than previously thought, and unidentified component(s) might contribute to the greater D binding in cancer patients compared to other study groups are suggested. Expand
Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases.
The results suggest that a total concentration of disopyramide within the therapeutic range may not be a reliable guide for a safe dosing scheme in patients with severe nephrotic syndrome, particularly during the exacerbation period. Expand
Negligible Removal of Lidocaine During Arteriovenous Hemofiltration
We studied whether lidocaine would be effectively removed by a hemofiltration, and the data derived from the present study are discussed in relation to the dosage recommendation of thisExpand